|
a few things
Hi Vickie,
1. I'm pretty sure the esophageal issues are with oral administration. That does still leave the issues of heart arrhythmias and osteonecrosis of the jaw. However they are rare side effects.
2. Insurance denial is always worth appealing.
3. The studies that are reporting so far (Gnant's for example) are showing decrease in all mets, not just bone. One caveat about his study is that it included only hormone (ERPR) positive cancers, which do tend to be more likely to develop bone mets. So are the results relevant to ERPR negative cancer? Is there something about ERPR+ cancer's interaction with bone that explains why Zometa seemed to prevent all mets and if so, will that result be limited to the ERPR+?. We don't know for sure.
4. You're almost 4 years past treatment, right? There's no information at all about that circumstance.
No answers. But if you do want it, I'd suggest the first step would be to appeal denial. What's your bone density?
Debbie Laxague
|